Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 7/2016

01-07-2016 | Liver (S Cotler and E Kallwitz, Section Editors)

Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes

Authors: Humberto C. Gonzalez, Andrés Duarte-Rojo

Published in: Current Gastroenterology Reports | Issue 7/2016

Login to get access

Abstract

Treatment with direct-acting antiviral agents has revolutionized the approach to hepatitis C. We are now able to obtain high sustained virological response (SVR) rates, even in the historically difficult-to-treat patient populations. SVR translates into improved clinical outcomes, particularly overall and liver-related mortality, and benefits are more striking in patients with cirrhosis. A 2.5- to 5-fold risk reduction in the incidence of hepatocellular carcinoma and improvement in complications derived from portal hypertension have been reported as well. It is hypothesized that the benefits from SVR occur largely due to regression of fibrosis, which arises from the halt on the fibrogenic stimuli and activation of extracellular matrix reabsorption signals. Non-invasive markers of fibrosis are being utilized to assess regression, but it is still unclear how accurate they are in this clinical scenario. Interventions aiming to improve liver wellness and screening for cirrhosis-related complications should continue to be the norm after SVR.
Literature
1.
Thorlund K, Druyts E, Mills EJ. SVR12 is higher than SVR24 in treatment-naive hepatitis C genotype 1 patients treated with peginterferon plus ribavirin. Clin Epidemiol. 2014;6:49–58.CrossRefPubMedPubMedCentral
2.
Yoshida EM et al. Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. Hepatology. 2015;61(1):41–5.CrossRefPubMed
3.
Barritt AST, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology. 2012;142(6):1314–1323 e1.CrossRefPubMedPubMedCentral
4.
Lawitz E et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed
5.
Foster GR et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373(27):2608–17.CrossRefPubMed
6.••
Charlton M. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59. A study reporting the use of direct-acting antiviral agents in decompensated cirrhosis both in non-transplant patients and transplant recipients.CrossRefPubMed
7.•
Curry MP. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28. A study using one of the newest combinations of antiviral agents (one active drug is not FDA approved yet) in decompensated HCV-related cirrhosis.CrossRefPubMed
8.
van der Meer AJ et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.CrossRefPubMed
9.
10.•
Nyberg LM. The association of sustained virological response and all-cause mortality after interferon-based therapy for chronic hepatitis C in a large U.S. community-based health care delivery system. Hepatology. 2015;62(1):252A. A community-based study confirming that SVR reduces all-cause mortality.CrossRef
11.
Ellis EL, Mann DA. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012;56(5):1171–80.CrossRefPubMed
12.
13.
Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood). 2008;233(2):109–22.CrossRef
14.
15.
Iredale JP et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 1998;102(3):538–49.CrossRefPubMedPubMedCentral
16.
Perez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu. 1979;14(Pt 2):183–213.PubMed
17.
Sun M, Kisseleva T. Reversibility of liver fibrosis. Clin Res Hepatol Gastroenterol. 2015;39 Suppl 1:S60–3.CrossRefPubMed
18.
Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis. 2001;21(3):427–36.CrossRefPubMed
19.
Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med. 2000;124(11):1599–607.PubMed
20.••
Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830–41. A comprehensive review of fibrosis regression pathophysiology.CrossRefPubMedPubMedCentral
21.
Castera L et al. Pain experienced during percutaneous liver biopsy. Hepatology. 1999;30(6):1529–30.CrossRefPubMed
22.
Gonzalez HC, Jafri SM, Gordon SC. Role of liver biopsy in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013;15(2):307.CrossRefPubMed
23.
24.
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–57.CrossRefPubMed
25.
Cholongitas E et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710–21.CrossRefPubMed
26.
Duarte-Rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol. 2012;11(4):426–39.PubMed
27.
Bernuth S. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis. 2015;48(3):291–7.CrossRefPubMed
28.
Martinez SM et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2011;33:138–48.CrossRefPubMed
29.
Poynard T et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9:128–33.CrossRefPubMed
30.
Poynard T et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303–13.CrossRefPubMed
31.
Maylin S et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135(3):821–9.CrossRefPubMed
32.
Mallet V et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149(6):399–403.CrossRefPubMed
33.
Everson GT et al. The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial. Aliment Pharmacol Ther. 2008;27(9):798–809.CrossRefPubMed
34.••
D’Ambrosio R. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56(2):532–43. A morphometric analysis of the liver parenchyma after SVR paired with improvement of liver function.CrossRefPubMed
35.
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–64.CrossRef
36.•
Bernuth S. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis. 2016;48(3):291–7. Evaluation of fibrosis regression with transient elastography after SVR.CrossRefPubMed
37.
Andersen ES et al. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23(1):41–4.CrossRefPubMed
38.
Calvaruso V et al. Fibrosis evaluation by transient elastography in patients with long-term sustained HCV clearance. Hepat Mon. 2013;13(5):e7176.PubMedPubMedCentral
39.
Hezode C et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34(6):656–63.CrossRefPubMed
40.
Crissien AM et al. Regression of advanced fibrosis or cirrhosis measured by elastography in patients with chronic hepatitis C who achieve sustained virological response after treatment for HCV. Hepatology. 2015;62:264A–5A.
41.••
D’Ambrosio R. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59(2):251–6. The authors analyzed transient elastography after HCV cure and called for new cutoff thresholds to stage fibrosis after SVR.CrossRefPubMed
42.
43.•
Poynard T. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol. 2013;59(4):675–83. A study reporting fibrosis improvement after SVR utilizing FibroTest.CrossRefPubMed
44.
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43.CrossRef
45.
Ioannou GN. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938–45, 945 e1-4.CrossRefPubMed
46.
Yoshida H et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131(3):174–81.CrossRefPubMed
47.
Aleman S et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57(2):230–6.CrossRefPubMed
48.•
Dieperink E. All-cause mortality and liver-related outcomes following successful antiviral treatment for chronic hepatitis C. Dig Dis Sci. 2014;59(4):872–80. A Veteran Administration study reporting improvement in overall and liver-related mortality after SVR.CrossRefPubMed
49.••
Messori A, Badiani B, Trippoli S. Achieving sustained virological response in hepatitis C reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures. Clin Drug Investig. 2015;35(12):843–50. A meta-analysis of 25 studies around the world documenting a decrease in risk for HCC after SVR.CrossRefPubMed
50.
Bruno S et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45(3):579–87.CrossRefPubMed
51.
Asahina Y et al. Alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology. 2013;58(4):1253–62.CrossRefPubMed
52.
Lok AS. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011;140(3):840–9, quiz e12.CrossRefPubMed
53.
Bruix J et al. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1990–9.CrossRefPubMed
54.
Sherman M et al. Screening for hepatocellular carcinoma: the rationale for the American Association for the Study of Liver Diseases recommendations. Hepatology. 2012;56(3):793–6.CrossRefPubMed
55.
Roberts S et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):932–7.CrossRefPubMed
56.
D’Ambrosio R et al. The course of esophageal varices in patients with hepatitis C cirrhosis responding to interferon/ribavirin therapy. Antivir Ther. 2011;16(5):677–84.CrossRefPubMed
57.
Bruno S et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology. 2010;51(6):2069–76.CrossRefPubMed
58.
de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.CrossRefPubMed
59.
Kee KM et al. Improvement of thrombocytopenia in hepatitis C-related advanced fibrosis patients after sustained virological response. Dig Dis Sci. 2013;58(2):556–61.CrossRefPubMed
60.
Taniguchi H et al. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy. J Gastroenterol Hepatol. 2006;21(1 Pt 2):281–7.CrossRefPubMed
61.•
van der Meer AJ. Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol. 2015. doi:10.​1111/​jgh.​13252. The authors report improvement of platelet count as a surrogate of decreasing portal hypertension after SVR.
62.••
Poordad F. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63(5):1493–505. A study with new antiviral agents for advanced cirrhosis and post-transplant HCV recurrence.CrossRefPubMed
63.
Afdhal N et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatol. 2014;60:S28.CrossRef
64.
Deterding K et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42(7):889–901.CrossRefPubMed
65.
Sallie R et al. Recurrence of hepatitis C following orthotopic liver transplantation: a polymerase chain reaction and histological study. J Hepatol. 1994;21(4):536–42.CrossRefPubMed
66.
Veldt BJ et al. Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection. Am J Transplant. 2008;8(11):2426–33.CrossRefPubMed
67.
Selzner N et al. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009;88(10):1214–21.CrossRefPubMed
68.
Kwo PY et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371(25):2375–82.CrossRefPubMed
69.
Pungpapong S et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015;61(6):1880–6.CrossRefPubMed
70.
Nair S, Satapathy SK, Gonzalez HC. Sofosbuvir and simeprevir for treatment of recurrent hepatitis C infection after liver transplant. Exp Clin Transplant. 2016. doi:10.​6002/​ect.​2015.​0289.
71.
Askgaard G et al. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: a prospective cohort study. J Hepatol. 2015;62(5):1061–7.CrossRefPubMed
72.
Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016;63(3):1026–40.CrossRefPubMed
73.
Macias-Rodriguez RU et al. Changes in hepatic venous pressure gradient induced by a physical exercise program in cirrhotic patients: a randomized open clinical trial. Hepatology. 2014;60(4):246–247A.
74.
Hezode C et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology. 2005;42(1):63–71.CrossRefPubMed
75.
Ranney DN et al. Marijuana use in potential liver transplant candidates. Am J Transplant. 2009;9(2):280–5.CrossRefPubMed
76.
77.
George SL et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-years follow-up of 150 patients. Hepatology. 2009;49(3):729–38.CrossRefPubMedPubMedCentral
78.
Asahina Y et al. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology. 2010;52(2):518–27.CrossRefPubMed
Metadata
Title
Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes
Authors
Humberto C. Gonzalez
Andrés Duarte-Rojo
Publication date
01-07-2016
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 7/2016
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-016-0508-y

Other articles of this Issue 7/2016

Current Gastroenterology Reports 7/2016 Go to the issue

Small Intestine (D Sachar, Section Editor)

Management and Complications of Short Bowel Syndrome: an Updated Review

GI Oncology (R Bresalier, Section Editor)

Gastric Cancer: How Can We Reduce the Incidence of this Disease?

Stomach and Duodenum (J Pisegna, Section Editor)

Eradication of Helicobacter pylori Infection

GI Oncology (R Bresalier, Section Editor)

Can Technology Improve the Quality of Colonoscopy?

Small Intestine (D Sachar, Section Editor)

Small Bowel Imaging: an Update

Inflammatory Bowel Disease (S Hanauer, Section Editor)

Practical Approaches to “Top–Down” Therapies for Crohn’s Disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits